65,437 trials
Alcoholism
Primary: Percentage of Heavy Drinking Days Over the Treatment Period — 14.75; 10.23; 19.77 Percentage of days — p=0.0245
Alcohol Dependence
Primary: Change From Baseline in Blood Oxygen-level-dependent (BOLD) Signal Activation Values Detected in the Reward Circuitry of the Brain in Alcohol-dependent Subjects After…
Migraine Disorders
Primary: Change in Frequency of Headache Episodes — 12.3; 13.4; -5.2; -5.3 Headache Episodes
Migraine Disorders
Primary: Change in Frequency of Headache Days — 19.9; 19.7; -9.0; -6.7 Headache Days
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Patients Experiencing Adverse Events — 22; 27 Participants
Need for Intravenous Catheter
Primary: Pain on Visual Analog Scale (VAS) — 18; 35 mm
Tuberculosis
Primary: Number of Participants With Laboratory Test or Clinical Judgment Resulting in the Need to Stop Study Medication — 6; 3 participants — p=>.05
Upper Limb Spasticity
Primary: Responder in Disability Assessment Scale (DAS) at Week 4 - Per Protocol Set — 51; 44 participants
Rheumatoid Arthritis
Primary: Total Exposure to Etanercept With Gaps — 4033.07; 341.98 Participant-years
Migraine
Primary: Number of Patients Reporting Pain Freedom at 2 Hours Postdose — 29; 88; 88; 39 Participants — p=<0.001
Skin Aging
Primary: Treatment Success — 89.08 % of participants
Prostate Cancer
Primary: Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight — 5; 6; 4; 7 participants
Alcoholism
Primary: Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) — 49; 51 Participants
Tetanus · Diphtheria · Pertussis
Primary: Percentage of Participants Who Achieved Seroprotection at Baseline and 30 Days Post-vaccination for Diphtheria and Tetanus at ≥ 0.1 IU/mL Level — 65; 69; 100; 100…
Autologous Stem Cell Transplantation
Primary: Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period — 65; 20; 9; 3 Participants